Regulatory and Responsible Research
RUO status, intended use, compounding, FDA peptide guidance, approved active versus approved product, peptide impurities, 503A evaluation, and responsible communication.
Overview
Regulatory science is the framework that distinguishes research materials, investigational drugs, compounded preparations, and approved products. The same molecule can sit in more than one category simultaneously, with different obligations attached to each.
An approved drug product is a specific formulation, manufactured under defined controls, labeled for defined indications, and reviewed by a regulatory authority. An approved active ingredient is the substance characterized within that approval. Neither status is automatically transferred to a different formulation, a different manufacturer, or a different intended use.
Research Use Only (RUO) describes the labeled status of a material intended for laboratory research. It is not a clinical claim, an efficacy claim, or a substitute for an Investigational New Drug application. Materials supplied for research must not be used in humans or for therapeutic purposes.
Compounding regulations, particularly under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, define what may be compounded, by whom, and under what circumstances. Peptides have been subject to evolving FDA evaluation, with materials placed on category 2 lists or otherwise restricted based on safety, identity, and clinical evidence considerations.
This hub contextualizes those distinctions. The goal is not to advise on compliance, which requires individualized counsel, but to support accurate scientific and editorial framing of what a status does and does not mean.